Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crowley

Showing results (91-100 of 178) with videos related to

Pageof 18
Sort By:
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerAndrew G Nicholson, Kari Chansky, John Crowley, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerPeter Goldstraw, Kari Chansky, John Crowley, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.
Blood|January 12, 2013
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Saad Z Usmani, Alan Mitchell, Sarah Waheed, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Clinical and Experimental Immunology|July 2, 2024
Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19Elena Woods, Adriana Mena, Sophie Sierpinska, et al.
Pageof 18

Showing results (91-100 of 178) with videos related to

Sort By:
Pageof 18
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerAndrew G Nicholson, Kari Chansky, John Crowley, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerPeter Goldstraw, Kari Chansky, John Crowley, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.
Blood|January 12, 2013
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Saad Z Usmani, Alan Mitchell, Sarah Waheed, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Clinical and Experimental Immunology|July 2, 2024
Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19Elena Woods, Adriana Mena, Sophie Sierpinska, et al.
Pageof 18